Literature DB >> 31978603

ApoE and cerebral insulin: Trafficking, receptors, and resistance.

Elizabeth M Rhea1, Jacob Raber2, William A Banks3.   

Abstract

Central nervous system (CNS) insulin resistance is associated with Alzheimer's disease (AD). In addition, the apolipoprotein E4 (apoE4) isoform is a risk factor for AD. The connection between these two factors in relation to AD is being actively explored. We summarize this literature with a focus on the transport of insulin and apoE across the blood-brain barrier (BBB) and into the CNS, the impact of apoE and insulin on the BBB, and the interactions between apoE, insulin, and the insulin receptor once present in the CNS. We highlight how CNS insulin resistance is apparent in AD and potential ways to overcome this resistance by repurposing currently approved drugs, with apoE genotype taken into consideration as the treatment response following most interventions is apoE isoform-dependent. This review is part of a special issue focusing on apoE in AD and neurodegeneration. Published by Elsevier Inc.

Entities:  

Keywords:  Alzheimer's disease; Amyloid beta; Apolipoprotein E; Blood-brain barrier; Central nervous system insulin; Insulin receptor

Mesh:

Substances:

Year:  2020        PMID: 31978603      PMCID: PMC7050417          DOI: 10.1016/j.nbd.2020.104755

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  186 in total

Review 1.  ApoE genotype accounts for the vast majority of AD risk and AD pathology.

Authors:  Jacob Raber; Yadong Huang; J Wesson Ashford
Journal:  Neurobiol Aging       Date:  2004 May-Jun       Impact factor: 4.673

2.  Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Authors:  Suzanne Craft; Laura D Baker; Thomas J Montine; Satoshi Minoshima; G Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R Plymate; Pattie S Green; James Leverenz; Donna Cross; Brooke Gerton
Journal:  Arch Neurol       Date:  2011-09-12

Review 3.  Developmental origins of health and disease: a paradigm for understanding disease cause and prevention.

Authors:  Jerrold J Heindel; Laura N Vandenberg
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

4.  Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease.

Authors:  Nidhi Sharma; Antonella Tramutola; Chiara Lanzillotta; Andrea Arena; Carla Blarzino; Tommaso Cassano; D Allan Butterfield; Fabio Di Domenico; Marzia Perluigi; Eugenio Barone
Journal:  Neurobiol Dis       Date:  2019-02-06       Impact factor: 5.996

5.  Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.

Authors:  Chantel Kowalchuk; Pruntha Kanagasundaram; William Brett McIntyre; Denise D Belsham; Margaret K Hahn
Journal:  Psychoneuroendocrinology       Date:  2019-08-04       Impact factor: 4.905

6.  Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study.

Authors:  M F Elias; P K Elias; L M Sullivan; P A Wolf; R B D'Agostino
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

7.  Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin.

Authors:  W A Banks; J B Jaspan; W Huang; A J Kastin
Journal:  Peptides       Date:  1997       Impact factor: 3.750

8.  Intranasal insulin improves cerebral blood flow, Nrf-2 expression and BDNF in STZ (ICV)-induced memory impaired rats.

Authors:  N Rajasekar; Chandishwar Nath; Kashif Hanif; Rakesh Shukla
Journal:  Life Sci       Date:  2016-09-28       Impact factor: 5.037

9.  Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.

Authors:  Angela J Hanson; Jennifer L Bayer; Laura D Baker; Brenna Cholerton; Brian VanFossen; Emily Trittschuh; Robert A Rissman; Michael C Donohue; Setareh H Moghadam; Stephen R Plymate; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

View more
  13 in total

Review 1.  Breakdown of the blood-brain barrier: A mediator of increased Alzheimer's risk in patients with metabolic disorders?

Authors:  Corey J Frank; Ewan C McNay
Journal:  J Neuroendocrinol       Date:  2021-12-13       Impact factor: 3.627

Review 2.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

Review 3.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

4.  Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice.

Authors:  Andreas Giannisis; Kalicharan Patra; Anna K Edlund; Lur Agirrezabala Nieto; Joan Benedicto-Gras; Simon Moussaud; Andrés de la Rosa; Daniel Twohig; Tore Bengtsson; Yuan Fu; Guojun Bu; Greg Bial; Lander Foquet; Christina Hammarstedt; Stephen Strom; Kristina Kannisto; Jacob Raber; Ewa Ellis; Henrietta M Nielsen
Journal:  Mol Psychiatry       Date:  2022-04-13       Impact factor: 13.437

Review 5.  Leveraging Electrostatic Interactions for Drug Delivery to the Joint.

Authors:  Shreedevi Kumar; Blanka Sharma
Journal:  Bioelectricity       Date:  2020-06-17

6.  Healthy aging and the blood-brain barrier.

Authors:  William A Banks; May J Reed; Aric F Logsdon; Elizabeth M Rhea; Michelle A Erickson
Journal:  Nat Aging       Date:  2021-03-15

Review 7.  A historical perspective on the interactions of insulin at the blood-brain barrier.

Authors:  Elizabeth M Rhea; William A Banks
Journal:  J Neuroendocrinol       Date:  2021-01-12       Impact factor: 3.627

Review 8.  The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease.

Authors:  Courtney M Kloske; Donna M Wilcock
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

Review 9.  Intranasal Insulin for Alzheimer's Disease.

Authors:  Manfred Hallschmid
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

Review 10.  Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions.

Authors:  Mara Dierssen; Marta Fructuoso; María Martínez de Lagrán; Marzia Perluigi; Eugenio Barone
Journal:  Front Neurosci       Date:  2020-07-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.